Practical management of primary biliary cholangitis

被引:2
作者
Pares, Albert [1 ]
机构
[1] Univ Barcelona, IDIBAPS, CIBERehd, Liver Unit,Hosp Clin Barcelona, Carrer Villarroel 170, Barcelona 08036, Spain
关键词
Primary biliar cholangitis; Autoimmune disease; Patient management; ursodeoxycholic acid; Obeticholic acid; URSODEOXYCHOLIC ACID; BIOCHEMICAL RESPONSE; ALKALINE-PHOSPHATASE; CLINICAL-FEATURES; GRADING SYSTEM; END-POINTS; CIRRHOSIS; PROGRESSION; TRANSPLANTATION; PROGNOSIS;
D O I
10.17235/reed.2021.8219/2021
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary biliary cholangitis (PBC) is a chronic, cholestatic liver disease of autoimmune pathogenesis that mainly affects middle-aged women. Patients show elevated alkaline phosphatase and bilirubin levels as the disease progresses. The main symptoms of the disease are pruritus and fatigue, which interfere with the quality of life of patients. Progressive damage leading to end-stage liver disease may require liver transplantation. Despite the efficacy of ursodeoxycholic acid (UDCA), the current standard of care for PBC, up to 40 % of patients have an inadequate response to treatment, requiring a second-line therapy. Obeticholic acid is the only second-line treatment approved for PBC in combination with UDCA in adults with inadequate response to UDCA, or as monotherapy in patients intolerant to UDCA. Although different clinical guidelines for the diagnosis and management of PBC have been published, PBC remains challenging for many physicians. In this article we briefly review the main characteristics of the disease and include a practical, user-friendly algorithm for the diagnosis and management of PBC that was developed by Spanish PBC experts based on the European Association for the Study of the Liver recommendations.
引用
收藏
页码:410 / 417
页数:8
相关论文
共 66 条
[1]   Diagnosis and management of primary biliary cirrhosis [J].
Ali, Ahmad H. ;
Carey, Elizabeth J. ;
Lindor, Keith D. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (12) :1667-1678
[2]   Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid [J].
Angulo, P ;
Lindor, KD ;
Therneau, TM ;
Jorgensen, RA ;
Malinchoc, M ;
Kamath, PS ;
Dickson, ER .
LIVER, 1999, 19 (02) :115-121
[3]   Genetics and Epigenetics of Primary Biliary Cirrhosis [J].
Bianchi, Ilaria ;
Carbone, Marco ;
Lleo, Ana ;
Invernizzi, Pietro .
SEMINARS IN LIVER DISEASE, 2014, 34 (03) :255-264
[4]   Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis [J].
Bowlus, Christopher L. ;
Pockros, Paul J. ;
Kremer, Andreas E. ;
Pares, Albert ;
Forman, Lisa M. ;
Drenth, Joost P. H. ;
Ryder, Stephen D. ;
Terracciano, Luigi ;
Jin, Yuying ;
Liberman, Alexander ;
Pencek, Richard ;
Iloeje, Uche ;
MacConell, Leigh ;
Bedossa, Pierre .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (05) :1170-+
[5]   Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid [J].
Carbone, Marco ;
Mells, George F. ;
Pells, Greta ;
Dawwas, Muhammad F. ;
Newton, Julia L. ;
Heneghan, Michael A. ;
Neuberger, James M. ;
Day, Darren B. ;
Ducker, Samantha J. ;
Sandford, Richard N. ;
Alexander, Graeme J. ;
Jones, David E. J. .
GASTROENTEROLOGY, 2013, 144 (03) :560-+
[6]   Primary biliary cirrhosis [J].
Carey, Elizabeth J. ;
Ali, Ahmad H. ;
Lindor, Keith D. .
LANCET, 2015, 386 (10003) :1565-1575
[7]   AGE, BILIRUBIN AND ALBUMIN, REGARDLESS OF SEX, ARE THE STRONGEST INDEPENDENT PREDICTORS OF BIOCHEMICAL RESPONSE AND TRANSPLANTATION-FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS [J].
Cheung, A. C. ;
Lammers, W. J. ;
Hirschfield, G. M. ;
Invernizzi, P. ;
Mason, A. L. ;
Ponsioen, C. Y. ;
Floreani, A. ;
Corpechot, C. ;
Mayo, M. J. ;
Pares, A. ;
Battezzati, P. M. ;
Nevens, F. ;
Thorburn, D. ;
Kowdley, K. V. ;
Trivedi, P. J. ;
Kumagi, T. ;
Lleo, A. ;
LaRusso, N. ;
Boonstra, K. ;
Cazzagon, N. ;
Franceschet, I. ;
Poupon, R. ;
Caballeria, L. ;
Lindor, K. D. ;
Hansen, B. E. ;
Janssen, H. L. ;
Van Buuren, H. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S798-S799
[8]  
Chuang N, 2011, EXPERT REV GASTROENT, V5, P583, DOI [10.1586/EGH.11.66, 10.1586/egh.11.66]
[9]   Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis [J].
Corpechot, Christophe ;
Chazouilleres, Olivier ;
Belnou, Pierre ;
Montano-Loza, Aldo J. ;
Mason, Andrew ;
Ebadi, Maryam ;
Eurich, Dennis ;
Chopra, Sascha ;
Jacob, Dietmar ;
Schramm, Christoph ;
Sterneck, Martina ;
Bruns, Tony ;
Reuken, Philipp ;
Rauchfuss, Falk ;
Roccarina, Davide ;
Thorburn, Douglas ;
Gerussi, Alessio ;
Trivedi, Palak ;
Hirschfield, Gideon ;
McDowell, Patrick ;
Nevens, Frederik ;
Boillot, Olivier ;
Bosch, Alexie ;
Giostra, Emiliano ;
Conti, Filomena ;
Poupon, Raoul ;
Pares, Albert ;
Reig, Anna ;
Donato, Maria Francesca ;
Malinverno, Federica ;
Floreani, Annarosa ;
Russo, Francesco Paolo ;
Cazzagon, Nora ;
Verhelst, Xavier ;
Goet, Jorn ;
Harms, Maren ;
van Buuren, Henk ;
Hansen, Bettina ;
Carrat, Fabrice ;
Dumortier, Jerome .
JOURNAL OF HEPATOLOGY, 2020, 73 (03) :559-565
[10]   Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis [J].
Corpechot, Christophe ;
Carrat, Fabrice ;
Poujol-Robert, Armelle ;
Gaouar, Farid ;
Wendum, Dominique ;
Chazouilleres, Olivier ;
Poupon, Raoul .
HEPATOLOGY, 2012, 56 (01) :198-208